Kisspeptin
Kisspeptin is a neuropeptide that plays a central role in the hypothalamic-pituitary-gonadal axis by stimulating GnRH (gonadotropin-releasing hormone) secretion. It is being investigated for reproductive endocrinology applications including hypogonadism, fertility, and sexual function.
At a Glance
Category
Sexual Health
Demand
Emerging
Route
Subcutaneous injection, intravenous
FDA Status
Compounding eligibility varies; verify current FDA status before prescribing
Also Known As
How Kisspeptin Works
Kisspeptin binds to the KISS1R (GPR54) receptor on GnRH neurons in the hypothalamic arcuate and anteroventral periventricular nuclei, triggering pulsatile GnRH release into the hypophyseal portal system [1]. This stimulates anterior pituitary gonadotropin (LH and FSH) secretion, which drives gonadal steroidogenesis and gametogenesis [1]. Kisspeptin neurons integrate metabolic, circadian, and stress signals, functioning as the master regulator of reproductive axis activation and the gatekeeper of puberty onset [4].
Clinical Evidence
Dhillo et al. (2005) at Imperial College London demonstrated that intravenous kisspeptin-54 potently stimulates LH and FSH release in healthy men, with subsequent studies confirming similar effects in women [1]. Jayasena et al. (2014) showed kisspeptin-54 restores LH pulsatility in women with hypothalamic amenorrhea, a condition unresponsive to standard treatments [2]. Clinical trials at Hammersmith Hospital demonstrated kisspeptin can trigger oocyte maturation in IVF protocols with reduced ovarian hyperstimulation risk compared to hCG triggers [3]. fMRI studies have also shown kisspeptin-54 enhances limbic brain activity in response to sexual stimuli, supporting its role in desire [4].
Clinical Uses
Patient Selection and Screening
Primary candidates include patients with hypothalamic amenorrhea (functional or stress-related) [2], men with hypothalamic hypogonadism seeking to preserve fertility while restoring testosterone [1], and IVF patients at high risk for ovarian hyperstimulation syndrome [3]. Also emerging for patients with low libido associated with hypogonadotropic conditions [4]. Not appropriate for patients with gonadotropin-dependent cancers (breast, prostate) or primary gonadal failure where the axis upstream of the gonads is intact. Baseline LH, FSH, and sex hormone panels required before initiation.
Dosing and Administration
Kisspeptin-54 is typically dosed at 1.0 to 6.4 nmol/kg intravenously for acute stimulation testing or IVF trigger protocols [3]. Subcutaneous dosing for chronic hypogonadism is less established but ranges from 6.4 to 12.8 nmol/kg twice daily in research settings [2]. Kisspeptin-10 has a shorter half-life (approximately 4 minutes IV vs 28 minutes for kisspeptin-54) and may require more frequent dosing or continuous infusion [1]. For IVF oocyte maturation trigger, a single IV bolus of 1.6 nmol/kg kisspeptin-54 has been studied [3]. Protocols remain investigational and should be individualized based on LH/FSH response monitoring.
Route: Subcutaneous injection, intravenous
Protocol notes: Administered via subcutaneous or intravenous injection. Dosing protocols are still emerging and vary by clinical indication and formulation (kisspeptin-10 vs kisspeptin-54).
Safety and Monitoring
Potential Side Effects
- ● Facial flushing and warmth (common with IV administration)
- ● Injection site discomfort
- ● Mild abdominal discomfort or bloating
- ● Headache (infrequent)
- ● Transient tachycardia following IV bolus
Clinical Considerations
- ● Relatively novel clinical application; many uses are investigational
- ● Different kisspeptin fragments (10 vs 54) have different pharmacokinetics
- ● Monitor LH, FSH, and sex hormone levels
- ● Limited long-term safety data in clinical settings
Practice Economics
Kisspeptin positions practices at the forefront of reproductive endocrinology innovation, attracting fertility-focused patients and those seeking alternatives to exogenous testosterone that preserve spermatogenesis [1]. As research expands into libido enhancement [4] and IVF applications [3], early adopters gain competitive advantage. The investigational status commands premium pricing from patients seeking cutting-edge reproductive care unavailable at conventional fertility clinics.
FDA Category Status
Compounding eligibility varies; verify current FDA status before prescribing
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify current status before prescribing.
Pharmacy Integrations
Prescribe Kisspeptin through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
How does kisspeptin differ from traditional hormone replacement? expand_more
What is the clinical evidence for kisspeptin? expand_more
References
- Dhillo WS et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005;90(12):6609-15.
- Jayasena CN et al. Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea. Clin Pharmacol Ther. 2014;96(5):615-23.
- Abbara A et al. Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. J Clin Endocrinol Metab. 2015;100(9):3322-31.
- Comninos AN et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017;127(2):709-19.
Related Peptides in Sexual Health
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable regulations. Always verify FDA category status and compounding eligibility before prescribing.
Launch a Peptide Program With Karpa
Karpa handles intake, licensed prescribing, and direct-to-patient pharmacy fulfillment across all 50 states. No medical license required.
Book a Demo